A Double-Blinded, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Restless Legs Syndrome (RLS)

Trial Profile

A Double-Blinded, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Restless Legs Syndrome (RLS)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Restless legs syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Luitpold Pharmaceuticals
  • Most Recent Events

    • 23 Mar 2017 Planned End Date changed from 1 Nov 2017 to 1 Apr 2018.
    • 23 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
    • 28 Nov 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top